BACKGROUND: Examining transcriptional regulation by antidepressants in key neural circuits implicated in depression and understanding the relation to transcriptional mechanisms of susceptibility and natural resilience may help in the search for new therapeutic agents. Given the heterogeneity of treatment response in human populations, examining both treatment response and nonresponse is critical. METHODS: We compared the effects of a conventional monoamine-based tricyclic antidepressant, imipramine, and a rapidly acting, non-monoamine-based antidepressant, ketamine, in mice subjected to chronic social defeat stress, a validated depression model, and used RNA sequencing to analyze transcriptional profiles associated with susceptibility, resilience, and antidepressant response and nonresponse in the prefrontal cortex (PFC), nucleus accumbens, hippocampus, and amygdala. RESULTS: We identified similar numbers of responders and nonresponders after ketamine or imipramine treatment. Ketamine induced more expression changes in the hippocampus; imipramine induced more expression changes in the nucleus accumbens and amygdala. Transcriptional profiles in treatment responders were most similar in the PFC. Nonresponse reflected both the lack of response-associated gene expression changes and unique gene regulation. In responders, both drugs reversed susceptibility-associated transcriptional changes and induced resilience-associated transcription in the PFC. CONCLUSIONS: We generated a uniquely large resource of gene expression data in four interconnected limbic brain regions implicated in depression and its treatment with imipramine or ketamine. Our analyses highlight the PFC as a key site of common transcriptional regulation by antidepressant drugs and in both reversing susceptibility- and inducing resilience-associated molecular adaptations. In addition, we found region-specific effects of each drug, suggesting both common and unique effects of imipramine versus ketamine.
BACKGROUND: Examining transcriptional regulation by antidepressants in key neural circuits implicated in depression and understanding the relation to transcriptional mechanisms of susceptibility and natural resilience may help in the search for new therapeutic agents. Given the heterogeneity of treatment response in human populations, examining both treatment response and nonresponse is critical. METHODS: We compared the effects of a conventional monoamine-based tricyclic antidepressant, imipramine, and a rapidly acting, non-monoamine-based antidepressant, ketamine, in mice subjected to chronic social defeat stress, a validated depression model, and used RNA sequencing to analyze transcriptional profiles associated with susceptibility, resilience, and antidepressant response and nonresponse in the prefrontal cortex (PFC), nucleus accumbens, hippocampus, and amygdala. RESULTS: We identified similar numbers of responders and nonresponders after ketamine or imipramine treatment. Ketamine induced more expression changes in the hippocampus; imipramine induced more expression changes in the nucleus accumbens and amygdala. Transcriptional profiles in treatment responders were most similar in the PFC. Nonresponse reflected both the lack of response-associated gene expression changes and unique gene regulation. In responders, both drugs reversed susceptibility-associated transcriptional changes and induced resilience-associated transcription in the PFC. CONCLUSIONS: We generated a uniquely large resource of gene expression data in four interconnected limbic brain regions implicated in depression and its treatment with imipramine or ketamine. Our analyses highlight the PFC as a key site of common transcriptional regulation by antidepressant drugs and in both reversing susceptibility- and inducing resilience-associated molecular adaptations. In addition, we found region-specific effects of each drug, suggesting both common and unique effects of imipramine versus ketamine.
Authors: A L Brody; S Saxena; P Stoessel; L A Gillies; L A Fairbanks; S Alborzian; M E Phelps; S C Huang; H M Wu; M L Ho; M K Ho; S C Au; K Maidment; L R Baxter Journal: Arch Gen Psychiatry Date: 2001-07
Authors: Rachel J Donahue; John W Muschamp; Scott J Russo; Eric J Nestler; William A Carlezon Journal: Biol Psychiatry Date: 2014-01-08 Impact factor: 13.382
Authors: Carla Nasca; Danielle Zelli; Benedetta Bigio; Sonia Piccinin; Sergio Scaccianoce; Robert Nisticò; Bruce S McEwen Journal: Proc Natl Acad Sci U S A Date: 2015-11-16 Impact factor: 11.205
Authors: H S Mayberg; S K Brannan; J L Tekell; J A Silva; R K Mahurin; S McGinnis; P A Jerabek Journal: Biol Psychiatry Date: 2000-10-15 Impact factor: 13.382
Authors: Sandra M Villafuerte; Kamala Vallabhaneni; Elzbieta Sliwerska; Francis J McMahon; Elizabeth A Young; Margit Burmeister Journal: Psychiatr Genet Date: 2009-12 Impact factor: 2.458
Authors: Katharine E McCann; David M Sinkiewicz; Anna M Rosenhauer; Linda Q Beach; Kim L Huhman Journal: Mol Neurobiol Date: 2018-09-08 Impact factor: 5.590
Authors: Joseph R Scarpa; Mena Fatma; Yong-Hwee E Loh; Said Romaric Traore; Theo Stefan; Ting Huei Chen; Eric J Nestler; Benoit Labonté Journal: Biol Psychiatry Date: 2020-01-22 Impact factor: 13.382
Authors: Lynnette A Averill; Christopher L Averill; Benjamin Kelmendi; Chadi G Abdallah; Steven M Southwick Journal: Curr Psychiatry Rep Date: 2018-03-28 Impact factor: 5.285
Authors: Nabil Karnib; Rim El-Ghandour; Lauretta El Hayek; Patrick Nasrallah; Mohamad Khalifeh; Nour Barmo; Vanessa Jabre; Pascale Ibrahim; Maria Bilen; Joseph S Stephan; Edward B Holson; Rajiv R Ratan; Sama F Sleiman Journal: Neuropsychopharmacology Date: 2019-01-08 Impact factor: 7.853